300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Enters Into $2 Billion Accelerated Share Repurchase Agreement
Announces strategic investment in LLC
Stockholders Approve Charter Amendments at 2026 Annual Meeting
Announces results for first quarter 2026
.2CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints
Annual Report to Security Holders
Boston Scientific Enters $3 Billion Revolving Credit Agreement
Elects Cathy Smith and Christophe Weber to Board of Directors
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-4/A
S-4
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Free Writing Prospectus